Core Insights - Alumis announced that its experimental pill achieved the primary endpoint in two late-stage studies involving patients with a specific type of skin disease [1] Company Summary - The experimental pill developed by Alumis is aimed at treating a type of skin disease and has shown positive results in late-stage clinical trials [1]

Roche’s experimental pill reduced the risk of an invasive return of a form of breast cancer in a study that underscores the drug’s blockbuster potential https://t.co/3uFkpw9GAS ...

Clinical Trial Results - Lilly's experimental pill resulted in patients shedding approximately 11% of their body weight [1] Market Expectations - The 11% weight loss result falls on the lower end of Wall Street's expectations [1]